Mark Ratcliffe

415 total citations
9 papers, 324 citations indexed

About

Mark Ratcliffe is a scholar working on Economics and Econometrics, Psychiatry and Mental health and Immunology. According to data from OpenAlex, Mark Ratcliffe has authored 9 papers receiving a total of 324 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Economics and Econometrics, 3 papers in Psychiatry and Mental health and 2 papers in Immunology. Recurrent topics in Mark Ratcliffe's work include Health Systems, Economic Evaluations, Quality of Life (7 papers), Schizophrenia research and treatment (3 papers) and Economic and Environmental Valuation (2 papers). Mark Ratcliffe is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (7 papers), Schizophrenia research and treatment (3 papers) and Economic and Environmental Valuation (2 papers). Mark Ratcliffe collaborates with scholars based in United Kingdom, Spain and United States. Mark Ratcliffe's co-authors include Josep María Haro, Diego Novick, David L. Suarez, J.P. Lépine, Jordi Alonso, Julia Langham, Sue Langham, Hans‐Peter Goertz, Stathis Kontodimas and Frank Windmeijer and has published in prestigious journals such as BMC Medical Research Methodology, Progress in Neuro-Psychopharmacology and Biological Psychiatry and Journal of Clinical Psychopharmacology.

In The Last Decade

Mark Ratcliffe

9 papers receiving 312 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Ratcliffe United Kingdom 7 162 108 60 48 36 9 324
Natalie C. Edwards United States 11 162 1.0× 93 0.9× 35 0.6× 49 1.0× 14 0.4× 21 415
Susan Gabriel United States 5 196 1.2× 22 0.2× 28 0.5× 56 1.2× 32 0.9× 10 397
A Schmeding Germany 5 81 0.5× 85 0.8× 37 0.6× 32 0.7× 63 1.8× 7 306
Dee Lin United States 10 184 1.1× 35 0.3× 62 1.0× 44 0.9× 3 0.1× 45 284
Saifuddin Kharawala United States 8 77 0.5× 12 0.1× 21 0.3× 27 0.6× 85 2.4× 13 225
Kate Sitnikova Netherlands 9 67 0.4× 14 0.1× 28 0.5× 31 0.6× 3 0.1× 13 335
Lars Wilkinson Denmark 11 90 0.6× 20 0.2× 20 0.3× 61 1.3× 2 0.1× 23 450
Jessica Brewster‐Jordan United States 7 76 0.5× 55 0.5× 26 0.4× 21 0.4× 9 408
Natalie Uhlenbusch Germany 8 25 0.2× 28 0.3× 6 0.1× 46 1.0× 5 0.1× 19 257
Rebecca Jacoby Israel 9 53 0.3× 8 0.1× 12 0.2× 24 0.5× 6 0.2× 30 254

Countries citing papers authored by Mark Ratcliffe

Since Specialization
Citations

This map shows the geographic impact of Mark Ratcliffe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Ratcliffe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Ratcliffe more than expected).

Fields of papers citing papers by Mark Ratcliffe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Ratcliffe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Ratcliffe. The network helps show where Mark Ratcliffe may publish in the future.

Co-authorship network of co-authors of Mark Ratcliffe

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Ratcliffe. A scholar is included among the top collaborators of Mark Ratcliffe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Ratcliffe. Mark Ratcliffe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Coyle, Doug, Isabelle Durand‐Zaleski, Louis P. Garrison, et al.. (2020). HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. The European Journal of Health Economics. 21(9). 1421–1437. 50 indexed citations
2.
Walker, Andrew, et al.. (2018). PP40 HTA Evaluations Of Combination Drugs: Positive Reimbursement Solutions. International Journal of Technology Assessment in Health Care. 34(S1). 80–81. 1 indexed citations
3.
Nicholson, Lindsay, et al.. (2017). Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?. ClinicoEconomics and Outcomes Research. Volume 9. 327–342. 27 indexed citations
4.
Langham, Sue, Julia Langham, Hans‐Peter Goertz, & Mark Ratcliffe. (2011). Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: A systematic and critical review. BMC Medical Research Methodology. 11(1). 32–32. 44 indexed citations
5.
Knapp, Martín, Frank Windmeijer, Jacqueline Brown, et al.. (2008). Cost-Utility Analysis of Treatment with Olanzapine Compared with Other Antipsychotic Treatments in Patients with Schizophrenia in the Pan-European SOHO Study. PharmacoEconomics. 26(4). 341–358. 22 indexed citations
6.
Haro, Josep María, Diego Novick, David L. Suarez, et al.. (2006). Remission and Relapse in the Outpatient Care of Schizophrenia. Journal of Clinical Psychopharmacology. 26(6). 571–578. 111 indexed citations
7.
Haro, Josep María, et al.. (2006). Methodological Aspects in the Assessment of Treatment Effects in Observational Health Outcomes Studies. Applied Health Economics and Health Policy. 5(1). 11–25. 40 indexed citations
8.
Haro, Josep María, et al.. (2006). Methodological Aspects in the Assessment of Treatment Effects in Observational Health Outcome Studies. 4 indexed citations
9.
Novick, Diego, Manuel Bousoño, David L. Suarez, et al.. (2005). Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: Results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 29(6). 972–982. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Natalie C. Edwards Breakdown of academic impact, for papers by Susan Gabriel Breakdown of academic impact, for papers by A Schmeding Breakdown of academic impact, for papers by Dee Lin Breakdown of academic impact, for papers by Saifuddin Kharawala Breakdown of academic impact, for papers by Kate Sitnikova Breakdown of academic impact, for papers by Lars Wilkinson Breakdown of academic impact, for papers by Jessica Brewster‐Jordan Breakdown of academic impact, for papers by Natalie Uhlenbusch Breakdown of academic impact, for papers by Rebecca Jacoby
Rankless by CCL
2026